A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
<p>Abstract</p> <p>β-(1,3)/(1,6) D-glucan, a component of the fungal cell wall, has been shown to stimulate the immune system, enhance hematopoiesis, amplify killing of opsonized tumor cells and increase neutrophil chemotaxis and adhesion. In view of these attributes, the β-glucans...
Main Author: | Weitberg Alan B |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Online Access: | http://www.jeccr.com/content/27/1/40 |
Similar Items
-
Immune modulation by non-digestible and non-absorbable beta-1,3/1,6-glucan
by: Jan Raa
Published: (2015-05-01) -
beta-1,3-glucan modifying enzymes in Aspergillus fumigatus
by: Isabelle eMouyna, et al.
Published: (2013-04-01) -
Health effects of endotoxin and beta-1,3-D-glucan exposure
by: Wan, Gwo-Hwa, et al.
Published: (1998) -
Structural and functional studies of interactions between [beta]-1,3-glucan and the N-terminal domains of [beta]-1,3-glucan recognition proteins involved in insect innate immunity
by: Dai, Huaien
Published: (2013) -
Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence.
by: Antonella Torosantucci, et al.
Published: (2009-01-01)